Professional Services
Four service lines built on more than two decades of principal investigator experience across cardiometabolic and metabolic liver disease — delivered with the rigor that complex litigation and pharmaceutical decisions require.
Service Line 01
For attorneys handling complex pharmaceutical litigation, product liability, and mass tort matters, KPMD Research provides physician-level analysis grounded in trial data, regulatory science, and clinical practice. Dr. Weston's IME and expert witness work is defensible, thorough, and delivered within established legal timelines.
Comprehensive IMEs for personal injury, workers' compensation, and pharmaceutical liability matters. Structured reporting aligned with jurisdictional requirements across Florida, Texas, Arizona, and Illinois.
Detailed review and analysis of medical records, imaging studies, and clinical data for litigation support. Causation analysis, standard of care assessment, and damages evaluation.
Expert analysis for matters involving drug safety, adverse event causation, clinical trial design failures, and regulatory non-compliance. Subspecialty focus in MASH, GLP-1, and cardiovascular therapeutic categories.
Available for deposition and trial testimony in federal and state courts. Experience across plaintiff and defense engagements in complex multi-district litigation and mass tort proceedings.
Preliminary case assessment and early scientific merit evaluation to assist counsel in evaluating litigation viability prior to full engagement. Confidential and protected under work product.
Experienced with multi-district litigation dynamics and Plaintiff Steering Committee engagements. Capable of managing high-volume case portfolios within established production schedules.
Service Line 02
Dr. Weston is retained by leading expert networks serving institutional investors, hedge funds, private equity firms, and global pharmaceutical companies. Consultations focus on drug development intelligence, pipeline assessment, therapeutic market dynamics, and clinical data interpretation.
Structured advisory calls providing clinical perspective on pharmaceutical pipelines, trial data interpretation, FDA regulatory outcomes, and therapeutic market positioning in cardiometabolic and metabolic liver disease.
Expert perspective on late-stage clinical development programs, trial design quality, endpoint selection, and competitive landscape in MASH, GLP-1, obesity, and cardiovascular outcomes.
Advisory on FDA approval pathways, accelerated approval mechanisms, REMS requirements, and post-marketing commitments relevant to novel therapeutic agents in metabolic and cardiovascular categories.
Service Line 03
Strategic advisory retainers for pharmaceutical companies and emerging biotechs navigating indication selection, clinical program design, and medical affairs strategy in cardiometabolic disease. Dr. Weston's experience spanning 100+ sponsored trials across multiple sponsors provides a level of comparative insight that is rare in individual advisors.
Advisory on study design, endpoint selection, patient population definition, and statistical considerations for Phase II and III trials. Particular depth in MASH histological endpoints, MACE composite outcomes, and GLP-1 program design.
Strategic guidance on indication selection, competitive differentiation, and asset positioning for companies developing therapeutic candidates in metabolic, hepatic, and cardiovascular disease categories.
Advisory support for medical affairs functions including KOL engagement strategy, medical information infrastructure, advisory board composition, and scientific communication planning.
Service Line 04
Fee-for-service biostatistics, regulatory writing, and scientific publication support for sponsors, CROs, academic institutions, and independent investigators. These services are provided in association with Calix Sciences, LLC.
Statistical analysis planning, interim and final analysis execution, and biostatistical consultation for clinical trial programs and retrospective research in cardiometabolic disease.
Manuscript development, peer-review journal submission strategy, and publication planning for clinical trial results and retrospective analyses. Domain expertise in hepatology and cardiometabolic outcomes literature.
Clinical study reports, regulatory submission documents, and scientific dossier preparation for IND, NDA, and BLA submissions. Support for FDA interactions and response to agency information requests.